��ժҪ��Ϣ

[an error occurred while processing this directive]

��Ƥ��Բ�ѧ��־ 0, () 279-281 DOI: ISSN: 2096-5540 CN: 32-1880/R

��Ŀ¼ | ��Ŀ¼ | �� | �߼�� [��ӡ��ҳ] [�ر�]

��

	��չ��

	��Ϣ
	Supporting info
	PDFȫ��
	[HTMLȫ��]
	�ο��
	��뷴��
	�ѱ��Ƽ��
	��ҵ��
	��ù��
	��ñ��
	Email Alert
	��·��
	��Ϣ
	��Ĺؼ��
	��
	��
	��
	��
	л��
	��Ŀ�
	PubMed
	Article by
	Article by

��Ƥ��û��߽��:��о��²��

л��, ��Ŀ�

��ľ�ҽ��ѧ��ҽԺƤ��, ��710032

ժҪ��

��Ƥ��߽��ֵķ��ʹ��ֱ�ø��򵥡��ȫ��и��õ��,��Խ��Խ�ܵ��о��ߵĹ�ע��Ƥ��ϲ��ǰ��Ϊ��޷��͸��,�ڶ��ֶ��ʵ��,Ƥ��ѵõ�֤ʵ��ǻ��ϣ��Ӧ��ٴ��ļ��֮һ��Ƥ��ֲ��û��ΪԤ��Ƽ��;��

�ؼ����

Abstract:

Keywords:

�ո�� 2005-01-06 �޻�� ��淢��

DOI:

��Ŀ:

ͨѶ��:

��߼��:

�ο��ף�

[1] Kane A, Lloyd J, Zaffran M, et al. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world:model-based regional estimates. Bull World Health Organ, 1999, 77:801-807.
[2] Uchi H, Terao H, Koga T, et al. Cytokines and chemokines in the epidermis. J Dermatol Sci, 2000, 24(Suppl 1):S29-S38.
[3] Debenedictis C, Joubeh S, Zhang G, et al. Immune functions of the skin. Clin Dermatol, 2001, 19:573-585.
[4] Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci, 2001, 14:101-114.
[5] Wu H, Ramachandran C, Bielinska AU, et al. Topical transfection using plasmid DNA in a water-in-oil nanoemulsion. Int J Pharm,2001, 221:23-34.
[6] Choi MJ, Maibach HI. Topical vaccination of DNA antigens:topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol, 2003,16:271-282.
[7] Alexander MY, Akhurst RJ. Liposome-medicated gene transfer and expression via the skin. Hum Mol Genet, 1995, 4:2279-2285.
[8] Alexander MY, Bidichandani S, Robinson C, et al. Physical methods of gene delivery using keratinocytes as a target for somatic cell gene therapy. Gene Ther, 1994,1(Suppl 1):S57.
[9] Li L, Hoffman RM. The feasibility of targeted selective gene therapy of the hair follicle. Nat Med, 1995, 1:705-706.
[10] Niemiec SM, Latta JM, Ramachandran C, et al. Perifollicular transgenic expression of human interleukin-1 receptor antagonist protein following topical application of novel liposome-plasmid DNA formulations in vivo. J Pharm Sci, 1997, 86:701-708.
[11] Tang DC, Shi Z, Curiel DT. Vaccination onto bare skin. Nature,1997, 388:729-730.
[12] Shi Z, Zeng M, Yang G, et al. Protection against tetanus by needlefree inoculation of adenovirus-vectored nasal and epicutaneous vaccines. J Virol, 2001, 75:11474-11482.
[13] Cui Z, Mumper RJ. Chitosan-based nanoparticles for topical genetic immunization. J Control Release, 2001, 75:409-419.
[14] Cui Z, Fountain W, Clark M, et al. Novel ethanol-in-fluorocarbon microemulsions for topical genetic immunization. Pharm Res, 2003,20:16-23.
[15] Scharton-Kersten T, Yu J, Vassell R,et al. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants. Infect Immun, 2000, 68:5306-5313.
[16] Watabe S, Xin KQ, Ihata A,et al. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine,2001, 19:4434- 4444.
[17] Liu LJ, Watabe S, Yang J, et al. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigenspecific immune responses. Vaccine, 2001, 20:42-48.
[18] Bramson J, Dayball K, Evelegh C, et al. Enabling topical immunization via microporation:a novel method for pain-free and needlefree delivery of adenovirus-based vaccines. Gene Ther, 2003, 10:251-260.
[19] Kang M J, Kim CK, Kim MY, et al. Skin permeation, biodistribution,and expression of topically applied plasmid DNA. J Gene Med,2004, 6:1238-1246.